CN113332366A - Application of medical composition in preparing medicine for treating xerophthalmia - Google Patents
Application of medical composition in preparing medicine for treating xerophthalmia Download PDFInfo
- Publication number
- CN113332366A CN113332366A CN202010136501.8A CN202010136501A CN113332366A CN 113332366 A CN113332366 A CN 113332366A CN 202010136501 A CN202010136501 A CN 202010136501A CN 113332366 A CN113332366 A CN 113332366A
- Authority
- CN
- China
- Prior art keywords
- powder
- pharmaceutical composition
- eye
- dry eye
- tear
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/07—Retinol compounds, e.g. vitamin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
- A61K36/064—Saccharomycetales, e.g. baker's yeast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/287—Chrysanthemum, e.g. daisy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/45—Ericaceae or Vacciniaceae (Heath or Blueberry family), e.g. blueberry, cranberry or bilberry
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
- A61K36/638—Ligustrum, e.g. Chinese privet
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Ophthalmology & Optometry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention relates to an application of a medical composition in preparing a medicine for treating xerophthalmia, wherein natural substances such as medlar powder, chrysanthemum powder, blueberry powder, grape seed powder, bitter tea oil, zinc gluconate, selenium yeast, vitamin A, marigold powder and the like are used for replacing traditional western medicines to improve the tear volume of eyes, prolong the tear film rupture time of the eyes and further relieve the symptom of the xerophthalmia.
Description
Technical Field
The invention relates to a medical composition, in particular to an application of the medical composition in preparing a medicine for treating xerophthalmia.
Background
The eye is the organ of vision responsible for receiving light from the environment and producing vision. In the process of forming vision, light firstly passes through the transparent cornea and the crystal in the eye, and by means of the light-gathering function of the two structures, the light can be focused on the retina to form an image, and the light-sensitive cells in the retina are stimulated to convert light stimulation into electric signals, and the electric signals reach the brain vision area through the conduction of optic nerves, and the vision is formed under the signal processing of the nerve cells.
However, with the rapid development of modern technologies, in addition to the rapid mass production of 3C products (mobile phones, tablet computers, desk computers …, etc.), the time for using 3C products is also increasing. Thus, the incidence of eye-related disorders (dry eye, myopia, ocular hypertension, glaucoma …, etc.) also increases and the incidence of age decreases year by year.
In order to prevent any disorder of the eye, a number of different methods of soothing the eye have been proposed. For example, the patient may temporarily close the eyes for rest, look far away, massage the eyes, wear sunglasses, and take vitamins and eye drops …. However, once the eye diseases are detected, except for the diseases needing surgical treatment, most of the eye diseases are treated by using medicines, but the medicines have certain side effects.
In terms of dry eye, the disease is a very common disease of modern people, the incidence rate varies from 5% to 30% in all age groups, and the symptoms of dry eye, burning eye, red and swollen foreign body sensation, pain, photophobia and even hypopsia are presented. At present, the general idea holds that the causes are mainly divided into two main types: 1. insufficient lacrimal secretion and excessive lacrimal evaporation.
1. Inadequate tear secretion is the most common cause of dry eye, for example, inadequate sleep, decreased lacrimal gland function due to aging, or inflammation of the lacrimal gland due to autoimmune diseases, such as trauma, infection, autonomic dysfunction, chronic application of eye drops (e.g., glaucoma medications) or medications (e.g., hypertensives, sedatives, etc.), resulting in inadequate tear secretion. With respect to extended contact lens wear, tear secretion is sometimes affected by reduced corneal sensitivity.
2. Excessive tear evaporation is a cause of dry eye which is gradually emphasized in recent years, and diseases such as insufficient secretion of lipid layers caused by dysfunction of sebaceous glands of eyelids, deficiency of vitamin A, chronic conjunctivitis, pemphigoid, chemical burn and the like, and mucus layer secretion deficiency caused by deficiency of secretion of mucus layers are possible factors such as reduction of blinking times (for example, reduction of blinking times caused by long-time special attention on driving, staring at a television and playing a computer), working environment of strong wind drying in cold rooms or outdoors for a long time, even eyelid closure failure caused by eyelid diseases and the like.
The most common way to treat dry eye is artificial tears, which not only provide moistening function and add moisture, but also dilute inflammatory substances and reduce the osmotic pressure of tears, thus being the most commonly used therapy for dry eye patients.
In addition, steroid eye drops are also the first line of clinical advocated by health care agencies and are mainly used for quick relief of symptoms. However, about five percent of the population responds strongly to steroid eye drops, easily causing an increase in intraocular pressure, and is suspected of causing glaucoma. In addition, long-term use also risks causing early cataracts.
Therefore, although the existing medicines can treat the xerophthalmia, certain side effects still exist, and related eye diseases are usually prevented rather than treated, so that the effective components required for preventing the eye diseases are usually recommended to be obtained from diet or health-care food.
Therefore, it is a problem to be solved by those skilled in the art to prevent the occurrence of eye disorders (such as dry eye …, etc.), to improve the daily maintenance of eyes, to extract effective components from natural diet, and to prepare them.
Disclosure of Invention
The main purpose of the invention is to provide the application of the pharmaceutical composition in preparing the medicine for treating xerophthalmia, wherein natural substances such as medlar powder, chrysanthemum powder, blueberry powder, grape seed powder, bitter tea oil, zinc gluconate, selenium yeast, vitamin A, marigold powder and the like are used for improving the tear fluid volume of eyes, prolonging the tear fluid film rupture time of the eyes and further relieving the symptom of xerophthalmia.
In order to achieve the purpose and the effect, the invention discloses the application of a medical composition in preparing a medicine for treating xerophthalmia, wherein the medical composition comprises a wolfberry fruit powder, a chrysanthemum flower powder, a blueberry powder, a grape seed powder, bitter tea oil, zinc gluconate, selenium yeast, vitamin A and Chinese holly powder, and the medical composition is used for relieving the symptom of the xerophthalmia.
The present invention provides an embodiment consisting in the use of a pharmaceutical composition for the preparation of a medicament for the treatment of dry eye, wherein the pharmaceutical composition further comprises a cocoa powder, a microcrystalline cellulose and a magnesium stearate.
The present invention provides an embodiment consisting in the use of a pharmaceutical composition for the preparation of a medicament for the treatment of dry eye, wherein the marigold powder further comprises a xanthophyll.
The invention provides an embodiment, which is the application of a medical composition in preparing a medicine for treating xerophthalmia, wherein the blueberry powder further comprises anthocyanin.
The present invention provides an embodiment, which is contained in the use of a pharmaceutical composition for the preparation of a medicament for the treatment of dry eye, wherein the pharmaceutical composition is for increasing the amount of tear fluid in the eye.
The present invention provides an embodiment consisting in the use of a pharmaceutical composition for the preparation of a medicament for the treatment of dry eye, wherein the pharmaceutical composition is for prolonging the tear film break-up time of the eye.
Drawings
FIG. 1A: which is a schematic diagram of tear volume in one embodiment of the present invention;
FIG. 1B: which is a diagram illustrating the amount of tears for different experimental conditions corresponding to the eye distance according to an embodiment of the present invention;
FIG. 2A: a schematic of tear film break up time according to an embodiment of the present invention; and
FIG. 2B: which is a diagram illustrating tear volume for tear film break-up time for different experimental conditions, in accordance with an embodiment of the present invention.
Detailed Description
In order to provide a further understanding and appreciation for the structural features and advantages achieved by the present invention, the following detailed description of the presently preferred embodiments is provided:
modern people are very susceptible to dry eye due to the long period of time in which they use 3C products, which varies from 5% to 30% in age-related groups, and presents symptoms such as dryness, burning, redness and swelling of foreign bodies, pain, photophobia and even vision loss. At present, the general idea holds that the causes are mainly divided into two main types: insufficient tear secretion and excessive tear evaporation.
Among them, the insufficient amount of lacrimal secretion in human body is the most common dry eye cause, such as the decrease of lacrimal gland function in aging, or the hormonal change in climacteric women, resulting in the insufficient amount of lacrimal secretion; many people have a reduced blinking frequency due to long-term fixation on a computer screen or a mobile phone, or wear contact lenses for a long time, which results in a reduction in the amount of tears on the surface of the eye to induce dry eye, and in addition, some of them are associated with autoimmune disorders and diseases or taking diuretics, antihistamines, anti-depression drugs, etc.
The reason why the amount of tear evaporation is too high is a cause of dry eye which has been receiving attention in recent years, and some people have difficulty in discharging oil due to inflammation caused by eye infection; some climacteric women are caused by hormone change in vivo, the oil dissolving point of meibomian glands is increased, so that the oil is discharged out unsmoothly, the tear is evaporated too fast, except eyelid sebaceous gland diseases and eyelid insufficiency, the women are in an air-conditioned dry environment for a long time, and eye allergy, vitamin A deficiency and the like caused by season exchange are also reasons for the too fast tear evaporation.
The most common way to treat dry eye is artificial tears, which not only provide moistening function and add moisture, but also dilute inflammatory substances and reduce the osmotic pressure of tears, thus being the most commonly used therapy for dry eye patients.
In addition, steroid eye drops are also the first line of clinical advocated by health care agencies and are mainly used for quick relief of symptoms. However, about five percent of the population responds strongly to steroid eye drops, easily causing an increase in intraocular pressure, and is suspected of causing glaucoma. In addition, long-term use also risks causing early cataracts.
In view of the influence of certain side effects of the traditional western medicine of eyes. Accordingly, the present invention provides a use of a pharmaceutical composition for preparing a medicament for treating dry eye, so as to solve the problems caused by the prior art.
The invention further includes features, associated structures and methods that are described in the following:
the invention relates to an application of a medical composition in preparing a medicine for treating xerophthalmia, wherein the medical composition comprises a wolfberry fruit powder, a chrysanthemum flower powder, a blueberry powder, a grape seed powder, bitter tea oil, zinc gluconate, selenium yeast, vitamin A and Chinese holly powder, and the medical composition is used for relieving the symptom of the xerophthalmia.
EXAMPLE 1 composition of pharmaceutical composition
Firstly, the composition proportion in the medical composition is that the medlar powder is 37.5 percent, the chrysanthemum powder is 31.25 percent, the blueberry powder is 2.5 percent, the grape seed powder is 2.5 percent, the zinc gluconate is 0.25 percent, the selenium yeast is 0.25 percent, the vitamin A content is 0.03 percent, the marigold powder is 0.025 percent and the bitter tea oil is prepared according to the proportion.
Preparation of fructus Lycii powder (also flos Chrysanthemi powder or fructus Myrtilli powder or grape seed powder or flos Tagetis Erectae powder)
Drying the wolfberry fruit (also the chrysanthemum, the blueberry, the grape seed or the marigold), standing, cooling to room temperature, and crushing the wolfberry fruit (also the chrysanthemum, the blueberry, the grape seed or the marigold) by using a grinding device to obtain wolfberry fruit powder (also chrysanthemum powder, blueberry powder, grape seed powder or marigold powder).
Acquisition of zinc gluconate, selenium yeast and vitamin A
The ZINC GLUCONATE is available from ZINC GLUCONATE (14% ZINC) available from yun corporation, vitamin a is also available from powdered vitamin a (available from fuxin technologies, inc.) and the selenium yeast is available from wegian corporation, U.S.A..
Preparation of bitter tea oil
Baking bitter tea seeds, cooling the bitter tea seeds by a cooling tank, crushing the bitter tea seeds into powder, boiling and sterilizing the powder in a pot, taking out the powder and pressing the powder into cake shape, then applying pressure to the cake-shaped bitter tea seeds, cold pressing the bitter tea oil cake at low temperature until oil is fully squeezed out, and obtaining the bitter tea oil after precipitation and filtration.
In addition, the Marigold powder contains a xanthophyll, the Marigold powder in the pharmaceutical composition of the present invention contains a xanthophyll, the plant which is found to be most rich in xanthophyll is Marigold (Marigold), wherein the xanthophyll and Zeaxanthin (Zeaxanthin) contained in Marigold are both similar carotenes (carotenes) which cannot be synthesized by human body and must be taken in food, the xanthophyll can be found in the eyes, skin, cervix, heart and chest of human body, and is an important vitamin for maintaining the health of these parts, especially eyes, and the component ratio of the xanthophyll in the pharmaceutical composition of the present invention is 0.005%.
The blueberry powder contains anthocyanin, the blueberry is found to contain the blueberry anthocyanin (anthocyanium Oxycoccus Pigment) which is a purely natural anti-aging nutritional supplement, researches prove that the blueberry is the most effective antioxidant found by people at present, the anthocyanin is a natural sunlight covering substance and can prevent ultraviolet rays from invading the skin, the skin belongs to connective tissues, collagen and hard protein contained in the anthocyanin play an important role in the whole structure of the skin, and the anthocyanin accounts for 0.25 percent in the medicinal composition.
Wherein the pharmaceutical composition further comprises cocoa powder (available from Fissistigment GmbH), microcrystalline cellulose (available from Moxixing GmbH) and magnesium stearate (available from Shunqing practice GmbH), the content of the cocoa powder in the pharmaceutical composition is 10%, the content of the microcrystalline cellulose in the pharmaceutical composition is 14.695%, and the content of the magnesium stearate in the pharmaceutical composition is 0.5%.
Examples of the experiments
Animal grouping and tube feeding mode
The invention takes female ICR mice of six weeks old as experimental animals, divides the female ICR mice into five groups, and adopts the following grouping mode and experimental mode:
please refer to fig. 1A, which is a diagram of the amount of tears of an embodiment of the present invention, and fig. 1B, which is a diagram of the amount of tears corresponding to different experimental conditions of an ocular distance of an embodiment of the present invention, as shown in the figure, Blank is the above-mentioned normal control group, Damage is the injury control group, Oil + DoseL is the drug control group with low Dose of dry eye containing the pharmaceutical composition, Oil + Dose H is the drug control group with high Dose of dry eye containing the pharmaceutical composition, and AFT is the control group with artificial tears.
(1) Normal control group (Blank group), fed 0.2ml of 0.9% physiological saline only;
(2) injury control group (Damage group), fed with 0.2ml of 0.9% physiological saline and irradiated with UVB;
(3) using a low Dose of a drug group for dry eye containing the pharmaceutical composition (Oil + Dose L group), feeding 0.2ml of a drug consisting of the low Dose of the drug group components and 0.1ml of bitter tea Oil in a tube, and irradiating UVB;
(4) using a high-Dose medicine group (Oil + Dose H group) containing the medicine composition for the xerophthalmia, feeding 0.2ml of medicine consisting of high-Dose medicine components and 0.1ml of bitter tea Oil in a tube, and irradiating UVB; and
(5) the group of artificial tears (AFT group) was used, and 0.2ml of 0.9% physiological saline was fed to the tube and the artificial tears were administered, and UVB was irradiated.
Tear test (Tear volume) experimental method
The invention carries out experiments on the 0 th day, the 4 th day and the 7 th day, and carries out Tear volume Test (TV) after five groups are respectively fed with tubes, firstly, a small segment of filter paper is placed on the inner side of the canthus, the filter paper absorbs the tears of the eyes for about five minutes, and then the tears are sampled after the filter paper absorbs the tears, and then UVB irradiation is carried out on each group of ICR female mice.
Experimental method for Tear film Break Up Time test (Tear Break Up Time)
After completion of Tear test (Tear volume), Tear film Break-Up real Time test (TBUT) was performed at 4 hours intervals, and this test was completed by dropping fluorescent dye on the eyeball surface, fixing the mouse eye so that it does not blink temporarily, and waiting until the mouse cornea became dry, which was called TBUT, and the Time for detecting Tear film Break-Up in the mouse, and generally, TBUT in the mouse with dry eye symptoms was shortened.
Results of the experiment
As shown by the results of the Tear test (Tear volume), the groups administered with the pharmaceutical composition of the present invention in combination with bitter tea Oil (Oil + Dose L and Oil + Dose H groups) showed a greater amount of Tear secretion than the control group (Damage group) in terms of Tear amount, and the group administered with the pharmaceutical composition in combination with bitter tea Oil (Oil + Dose H group) showed a significant effect, which was better than the group administered with artificial tears (AFT group), showing that the pharmaceutical composition of the present invention in combination with bitter tea Oil had an effect of promoting Tear secretion after being fed.
Referring to fig. 2A, which is a schematic diagram of Tear film Break-Up Time according to an embodiment of the present invention, and fig. 2B, which is a schematic diagram of Tear amount according to different experimental conditions of Tear film Break-Up Time according to an embodiment of the present invention, it is shown that, at day 7, both the drug group for dry eye containing the pharmaceutical composition at a low Dose (Oil + DoseL group) and the drug group for dry eye containing the pharmaceutical composition at a high Dose (Oil + Dose H group) contribute to the improvement of Tear film Break-Up Time, and the effect is better than that of the group using artificial tears (AFT group).
The above experimental results show that the pharmaceutical composition of the invention is helpful for relieving xerophthalmia after being matched with the bitter tea oil, and the relieving effect is more obvious particularly in high-dose administration.
Therefore, according to the above results, it can be understood that the invention is the use of a pharmaceutical composition for preparing a medicament for treating xerophthalmia, and the natural substances such as wolfberry powder, chrysanthemum powder, blueberry powder, grape seed powder, bitter tea oil, zinc gluconate, selenium yeast, vitamin a, marigold powder and the like are used for replacing the traditional western medicines to improve the tear fluid volume of eyes and prolong the tear film rupture time of eyes, so as to further alleviate the symptom of xerophthalmia.
The medicinal composition is used for preparing the medicine for treating xerophthalmia, which is different from the traditional western medicines, and because the medicinal composition in the invention is obtained from food or plants, no side effect is generated after the medicinal composition is used, and no physical burden is caused to a human body.
The above description is only for the purpose of illustrating the preferred embodiments of the present invention and is not intended to limit the scope of the present invention, which is defined by the appended claims.
Claims (6)
1. The application of a medical composition in preparing a medicine for treating xerophthalmia is characterized in that the medical composition comprises a wolfberry fruit powder, a chrysanthemum flower powder, a blueberry powder, a grape seed powder, bitter tea oil, zinc gluconate, selenium yeast, vitamin A and Chinese holly powder, and the medical composition is used for relieving the symptom of the xerophthalmia.
2. The use of the pharmaceutical composition of claim 1 for the preparation of a medicament for the treatment of dry eye, wherein the pharmaceutical composition further comprises a cocoa powder, a microcrystalline cellulose and a magnesium stearate.
3. The use of the pharmaceutical composition of claim 1 for the preparation of a medicament for the treatment of dry eye, wherein the marigold powder further comprises a xanthophyll.
4. The use of the pharmaceutical composition of claim 1 for the preparation of a medicament for the treatment of dry eye, wherein the blueberry powder further comprises an anthocyanin.
5. The use of the pharmaceutical composition of claim 1 for the preparation of a medicament for the treatment of dry eye, wherein the pharmaceutical composition is for increasing the amount of tear fluid in the eye.
6. Use of the pharmaceutical composition of claim 1 for the preparation of a medicament for the treatment of dry eye, wherein the pharmaceutical composition is for prolonging tear film break-up time of the eye.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010136501.8A CN113332366A (en) | 2020-03-02 | 2020-03-02 | Application of medical composition in preparing medicine for treating xerophthalmia |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010136501.8A CN113332366A (en) | 2020-03-02 | 2020-03-02 | Application of medical composition in preparing medicine for treating xerophthalmia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113332366A true CN113332366A (en) | 2021-09-03 |
Family
ID=77467304
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010136501.8A Pending CN113332366A (en) | 2020-03-02 | 2020-03-02 | Application of medical composition in preparing medicine for treating xerophthalmia |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113332366A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115844977A (en) * | 2022-12-30 | 2023-03-28 | 福建农林大学 | Bacteriostatic herbal composition for dry eye SPA atomization and preparation method thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1141786A (en) * | 1995-07-28 | 1997-02-05 | 李震超 | Eyedrops for treatment of external eye disease |
| CN103566067A (en) * | 2012-07-19 | 2014-02-12 | 上海诺金科生物科技有限公司 | Composition for treating eye diseases and its application |
| CN104256827A (en) * | 2014-10-17 | 2015-01-07 | 山东禹王制药有限公司 | Vision-improving oral liquid and preparation method thereof |
| CN107183597A (en) * | 2017-06-07 | 2017-09-22 | 长春金荷药业有限公司 | A kind of indigo fruit functional food |
| CN110892987A (en) * | 2017-11-05 | 2020-03-20 | 周学义 | Preparation method of wolfberry syrup |
-
2020
- 2020-03-02 CN CN202010136501.8A patent/CN113332366A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1141786A (en) * | 1995-07-28 | 1997-02-05 | 李震超 | Eyedrops for treatment of external eye disease |
| CN103566067A (en) * | 2012-07-19 | 2014-02-12 | 上海诺金科生物科技有限公司 | Composition for treating eye diseases and its application |
| CN104256827A (en) * | 2014-10-17 | 2015-01-07 | 山东禹王制药有限公司 | Vision-improving oral liquid and preparation method thereof |
| CN107183597A (en) * | 2017-06-07 | 2017-09-22 | 长春金荷药业有限公司 | A kind of indigo fruit functional food |
| CN110892987A (en) * | 2017-11-05 | 2020-03-20 | 周学义 | Preparation method of wolfberry syrup |
Non-Patent Citations (1)
| Title |
|---|
| 张大禄: "《科学解读保健食品 选对吃好保健康》", 31 January 2016, 中国医药科技出版社 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115844977A (en) * | 2022-12-30 | 2023-03-28 | 福建农林大学 | Bacteriostatic herbal composition for dry eye SPA atomization and preparation method thereof |
| CN115844977B (en) * | 2022-12-30 | 2024-03-29 | 福建农林大学 | Antibacterial herbal composition capable of being used for dry eye SPA atomization and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109091675B (en) | Compound low-concentration atropine medicine eye drops and preparation method thereof | |
| CN104147081A (en) | Blueberry lutein soft capsule for improving eyesight and manufacturing method thereof | |
| CN109010761A (en) | A kind of eye externally applied drug and preparation method thereof alleviated visual fatigue and improve eyesight | |
| US20210169779A1 (en) | Ophthalmic drug preparation and uses thereof | |
| CN106539083A (en) | It is a kind of to be used to prevent and treat diabetic retinopathy, alleviate asthenopic compositionss | |
| CN113332366A (en) | Application of medical composition in preparing medicine for treating xerophthalmia | |
| CN104971304A (en) | Xerophthalmia treatment medicine | |
| CN106262850A (en) | A kind of miscellaneous grain crops health instant powder and production technology | |
| CN110448618A (en) | A kind of Chinese medicine preparation and preparation method thereof for treating eyesight | |
| CN109260397A (en) | A kind of Chinese medicine composition for treating Vascular retinopathy | |
| CN111329915B (en) | Composition for relieving asthenopia of old people and hydrophilic gel thereof | |
| CN212631046U (en) | Eye shield with plant nano crystal for improving eyesight | |
| CN105326954B (en) | A kind of Chinese medicine composition and preparation method thereof for treating blear-eye | |
| CN113413415A (en) | Lanosterol eye drops and preparation method thereof | |
| CN113350451A (en) | Use of pharmaceutical composition for preparing medicine for treating intraocular pressure | |
| CN102940753B (en) | Pills for treating glaucoma and preparation method | |
| CN108498615A (en) | A kind of Chinese herb medicine eye health-care patch and preparation method thereof improving eyes based on nitric oxide principle | |
| CN109432191A (en) | A kind of eye sticker and preparation method thereof for alleviating asthenopia | |
| AU2020352751B2 (en) | Composition of a dietary supplement and/or a nutritional additive for food, a unitary dosage form of said composition, and their use for improvement of the quality of visual performance including contrast sensitivity in persons in need of such an improvement, including persons suffering from at least one eye disease, particularly vitreous floaters | |
| CN112107623B (en) | Traditional Chinese medicine composition for improving meibomian gland function | |
| CN113332362A (en) | Application of pharmaceutical composition in preparing medicine for treating pseudomyopia | |
| CN106728581B (en) | Application of pharmaceutical composition in preparation of medicine for treating asthenopia caused by long-term visual impairment | |
| CN103006847B (en) | Eye drops for treating uveitis and preparation method thereof | |
| CN1222304C (en) | Medicine for treating turbid vitrious body and its prepn | |
| CN114288347A (en) | Medicine and food composition for benefiting eyesight and improving eyesight and preparation method and application method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20210903 |